MYGN Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $206 million, a 4% decrease year-over-year. Adjusting for headwinds, the underlying growth rate was approximately 5%.
Testing Volume: Increased by 3% overall, with significant growth in hereditary cancer testing (MyRisk) at 11% and GeneSight at 8%.
Adjusted Gross Margin: Strong at 70.1%.
Adjusted EBITDA: Reported at $10.3 million.
Adjusted Operating Expenses: Decreased by $1 million year-over-year, reflecting cost discipline.
Free Cash Flow: Positive adjusted free cash flow of $18.6 million, though not expected to repeat in Q4.

2. Strategic Updates and Business Highlights

Focus on Cancer Care Continuum: Myriad is concentrating on expanding its oncology portfolio, particularly through the MyRisk test and new partnerships (e.g., with SOPHiA GENETICS for biomarker validation).
New Product Launches: An updated MyRisk test is set to launch in November 2025, and a new Prolaris prostate cancer test combining molecular and AI technologies is expected in the first half of 2026.
Organizational Changes: Myriad is reallocating resources to enhance customer experience and market share, including expanding the commercial team and investing in new product launches.
Prenatal Testing: The FirstGene multiple prenatal screen is in early access, with a full commercial launch planned for 2026.

3. Forward Guidance and Outlook

2025 Financial Guidance: Reiterated revenue guidance of $818 million to $828 million, with gross margins between 69.5% and 70%.
Adjusted EBITDA Guidance: Expected between $27 million and $33 million, with adjusted EPS projected to be a loss of $0.02 to a gain of $0.02.

4. Bad News, Challenges, or Points of Concern

Revenue Decline: The 4% year-over-year revenue decrease is attributed to factors including a prior period contribution that did not repeat and the impact of UnitedHealthcare's policy change on GeneSight.
ASP Pressure: Average revenue per test declined by 7%, influenced by changes in payer mix and the effects of the UnitedHealthcare policy.
Market Competition: Increased competition in the prenatal testing market, with new entrants affecting market share.
Operational Challenges: Previous EMR integration issues have impacted customer workflows, although improvements are being made.

5. Notable Q&A Insights

Growth vs. Profitability: Management emphasized a commitment to profitable growth, balancing investments in the cancer care continuum while managing operating expenses.
GeneSight's Future: Despite challenges, GeneSight remains a priority, with ongoing efforts to secure payer coverage and expand clinician adoption.
Market Dynamics: There is a recognition of competitive pressures in the NIPT market, but management is optimistic about future growth with new product launches.
Operational Improvements: Continued focus on reducing no-pay rates and enhancing revenue cycle management is expected to support ASP recovery in the long term.

Overall, while Myriad Genetics faces some headwinds, particularly in revenue and ASP, the company is strategically positioned for growth through new product launches and a focused approach to enhancing its oncology portfolio.

MYGN — Myriad Genetics, Inc.

Q3 2025 Earnings Call Summary